Radioimmunodetection of Prostatic Cancer
In Vivo Use of Radioactive Antibodies Against Prostatic Acid Phosphatase for Diagnosis and Detection of Prostatic Cancer by Nuclear Imaging
- David M. Goldenberg, ScD, MD;
- Frank H. DeLand, MD;
- Sidney J. Bennett, PhD;
- F. James Primus, PhD;
- M. Owens Nelson, MD;
- Robert C. Flanigan, MD;
- J. William McRoberts, MD;
- Andrew W. Bruce, MD;
- Donald E. Mahan, PhD
- From the Divisions of Experimental Pathology (Drs Goldenberg, Bennett, and Primus), Nuclear Medicine) (Dr DeLand), Hematology/Oncology (Dr Nelson), and Urology (Drs Flanigan and McRoberts), University of Kentucky and Veterans Administration Medical Centers, Lexington, and the Division of Urology, McGill University, Montreal (Drs Bruce and Mahan).
Abstract
Radioimmunodetection (RAID) of prostatic cancer is done by injecting131I-labeled rabbit antibody IgG against prostatic acid phosphatase (PAP) and performing total-body photoscans with a gamma scintillation camera. Of two patients tested, the PAP RAID scintiscans located the primary or recurrent prostatic cancers in both and showed no disease in the lungs of the patient shown subsequently to have lung cancer. The lung tumor nodules showing anti-PAP IgG accretion were assumed to be of prostatic cancer origin, since one of the original tumors removed from this patient's other lung a year earlier stained for PAP by immunohistochemistry. This study showed that PAP RAID can locate primary and metastatic tumors of prostatic origin.
(JAMA 1983;250:630-635)
Footnotes
-
Reprint requests to Division of Experimental Pathology, Room 243, Research Building 3, University of Kentucky, Lexington, KY 40536 (Dr Goldenberg).
